Search results for "Azine"

showing 10 items of 1589 documents

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

2020

Inhibidor d'AKT; Càncer avançat; Fase I Inhibidor de AKT; Cáncer avanzado; Fase I AKT inhibitor; Advanced cancer; Phase I Background This phase Ib study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the oral AKT inhibitor ipatasertib and chemotherapy or hormonal therapy in patients with advanced or metastatic solid tumors to determine combined dose-limiting toxicities (DLTs), maximum tolerated dose, and recommended phase II doses and schedules. Patients and methods The clinical study comprised four combination treatment arms: arm A (with docetaxel), arm B [with mFOLFOX6 (modified leucovorin, 5-fluorouracil, and oxaliplatin)], arm C (with paclitaxel), and …

Male0301 basic medicinemedicine.medical_specialtyMaximum Tolerated Dosemedicine.medical_treatmentCàncer - Quimioteràpia:Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores]GastroenterologyAKT inhibitorPiperazinesMedicaments antineoplàstics - Efectes secundaris:neoplasias [ENFERMEDADES]03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy Protocols:Other subheadings::Other subheadings::/adverse effects [Other subheadings]medicineadvanced cancerHumansEnzalutamide:terapéutica::protocolos clínicos::protocolos antineoplásicos::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Adverse effectChemotherapybusiness.industryHematologyphase I:Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Oxaliplatin:Neoplasms [DISEASES]Pyrimidines030104 developmental biologyOncologyDocetaxelTolerabilityPaclitaxelchemistryResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisbusinessmedicine.drugAnnals of Oncology
researchProduct

Lamotrigine differently modulates 7-Nitroindazole and L-Arginine influence on Rat Maximal Dentate Gyrus Activation

2007

The effects induced on the maximal dentate gyrus activation (MDA) by administering the anticonvulsant lamotrigine (LTG), the selective inhibitor of neuronal nitric oxide synthase 7-nitroindazole (7-NI) and the precursor of nitric oxide (NO) synthesis L-arginine, alone or in combination, were studied in urethane anaesthetized rats. Either 7-NI or LTG alone administration reduced the number of convulsing animals following angular bundle (AB) stimulation; their combined treatment induced a further increase of the anticonvulsant effect as also demonstrated by the decrease of MDA and afterdischarge (AD) durations in the animals still responding to AB stimulation. On the contrary, the injection o…

Male7-NitroindazoleIndazolesArgininemedicine.medical_treatmentStimulationPharmacologyLamotrigineArginineLamotrigineNitric OxideSettore BIO/09 - FisiologiaNitric oxidechemistry.chemical_compoundSeizuresmedicineAnimalsEnzyme InhibitorsRats WistarBiological PsychiatryTriazinesDentate gyrusElectric StimulationRatsPsychiatry and Mental healthAnticonvulsantNeurologychemistryDentate GyrusAnticonvulsantsNeurology (clinical)Neuronal Nitric Oxide Synthasemedicine.drugLAMOTRIGINE NITRIC OXIDE EPILEPSY CONTROL
researchProduct

Mathematical modelling of in situ and in vitro efflux of ciprofloxacin and grepafloxacin

2005

Abstract The efflux process due to p-glycoprotein-like mechanisms of ciprofloxacin (CIP) and grepafloxacin (GRX) has been studied “in situ” in rats and “in vitro” in Caco-2 cells. The results were modelled by a curve fitting procedure which allowed the characterization of the passive (Pd) and carrier mediated parameters (Vm and Km) from the raw data without initial velocities estimation. CIP absorption in rat was characterized as a passive diffusion at the assayed concentrations. Although the involvement of an efflux transporter cannot be ruled out, its relevance in the transport of the fluoroquinolone is negligible. In GRX absorption, an efflux process is implicated and it is detected in b…

MaleAbsorption (pharmacology)In situCell Membrane PermeabilityPharmaceutical ScienceModels BiologicalPiperazinesDiffusionAnti-Infective AgentsCiprofloxacinIntestine SmallmedicineAnimalsHumansRats WistarAntibacterial agentChemistryTransporterIn vitroGrepafloxacinRatsPerfusionIntestinal AbsorptionBiochemistryPermeability (electromagnetism)BiophysicsEffluxCaco-2 CellsFluoroquinolonesmedicine.drugInternational Journal of Pharmaceutics
researchProduct

Gender differences in motivation and barriers for the practice of physical exercise in adolescence

2019

A total of 852 adolescents between 12 and 17 years of age were evaluated (M = 14.86, SD = 1.67), randomly selected among a population of secondary school and Baccalaureate students. We applied an &ldquo

MaleAdolescentHealth Toxicology and Mutagenesismedia_common.quotation_subjectbarrierscorrelation analysisPopulationeducationlcsh:MedicinePhysical exercise030204 cardiovascular system & hematologySociodemographic data6102 Psicología del Niño y del AdolescenteArticleCompetition (economics)03 medical and health sciencesSex Factors0302 clinical medicinemotivationphysical exerciseSurveys and QuestionnairesHumans030212 general & internal medicineChildStudentseducationExercisemedia_commoneducation.field_of_studySchoolsLazinesslcsh:RPublic Health Environmental and Occupational HealthSocial recognition3212 Salud PublicaAdolescent BehaviorCorrelation analysisFemaleadolescencePsychologyClinical psychology
researchProduct

Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice

2010

AbstractBackgroundNumerous reports indicate that MDMA users consume other psychoactive drugs, among which cannabis is one of the most common. The aim of the present study was to evaluate, using the conditioned place preference, the effect of the cannabinoid agonist WIN 55,212-2 on the rewarding effects of MDMA in mice.MethodsIn the first experiment adolescent mice were initially conditioned with 1.25, 2.5 or 5 mg/kg of MDMA or 0.1 or 0.5 mg/kg of WIN and subsequently with both drugs. Reinstatement of the extinguished preference by priming doses was performed in the groups that showed CPP. In the second experiment, animals were conditioned with 2.5 or 5 mg/kg of MDMA and, after extinction, r…

MaleAgonistCannabinoid receptormedicine.drug_classMorpholinesN-Methyl-34-methylenedioxyamphetamineCognitive Neurosciencemedicine.medical_treatmentMice Inbred StrainsNaphthalenesPharmacologylcsh:RC346-429Extinction PsychologicalMiceBehavioral NeuroscienceSerotonin AgentsPiperidinesReceptor Cannabinoid CB1RewardRimonabantConditioning Psychologicalmental disordersmedicineAnimalsDrug Interactionslcsh:Neurology. Diseases of the nervous systemBiological PsychiatryBrain ChemistryBehavior AnimalDose-Response Relationship DrugbiologyResearchMDMAGeneral MedicineExtinction (psychology)Calcium Channel Blockersbiology.organism_classificationConditioned place preferenceBenzoxazinesNeuroprotective AgentsPyrazolesCannabinoidCannabisRimonabantPsychologypsychological phenomena and processesmedicine.drugBehavioral and Brain Functions
researchProduct

Acute blockade of CB1 receptor leads to reinstatement of MDMA-induced conditioned place preference

2011

Cannabis is one of the drugs most commonly consumed in combination with ecstasy (3,4-methylenedioxymethamphetamine, MDMA). Although numerous studies have attempted to further our understanding of the role of the cannabinoid system in drug abuse, few have focused on how it influences the rewarding effects of MDMA. The aim of the present study was to evaluate the role of the CB1 cannabinoid receptor in vulnerability to reinstatement of a MDMA-induced conditioned place preference (CPP). Mice were first conditioned with 5mg/kg of MDMA. Once the preference had been extinguished, a priming dose of MDMA, alone or plus the CB1 cannabinoid agonist WIN 55,212-2 (0.1 and 0.5mg/kg) or the CB1 cannabino…

MaleAgonistCannabinoid receptormedicine.drug_classMorpholinesN-Methyl-34-methylenedioxyamphetaminemedicine.medical_treatmentDrug-Seeking BehaviorClinical BiochemistryEcstasyNaphthalenesPharmacologyToxicologyBiochemistryMiceBehavioral NeuroscienceReceptor Cannabinoid CB1Conditioning Psychologicalmental disordersmedicineAnimalsBiological PsychiatryPharmacologyDose-Response Relationship DrugCannabinoidsbusiness.industrymusculoskeletal neural and ocular physiologyAntagonistMDMAEndocannabinoid systemConditioned place preferenceBenzoxazinesnervous systemlipids (amino acids peptides and proteins)Cannabinoidbusinesspsychological phenomena and processesmedicine.drugPharmacology Biochemistry and Behavior
researchProduct

Long-term effects on cortical glutamate release induced by prenatal exposure to the cannabinoid receptor agonist (r)-(+)-[2,3-dihydro-5-methyl-3-(4-m…

2003

The aim of the present in vivo microdialysis study was to investigate whether prenatal exposure to the CB1 receptor agonist WIN55,212-2 mesylate (WIN; (R)-()-(2,3- dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo(1,2,3-de)- 1,4-benzoxazin-6-yl)-1-naphthalenylmethanone), at a dose of 0.5 mg/kg (s.c. from the fifth to the 20th day of gestation), that causes neither malformations nor overt signs of toxicity, influences cortical glutamate extracellular levels in adult (90- day old) rats. Dam weight gain, pregnancy length and litter size at birth were not significantly affected by prenatal treatment with WIN. Basal and K-evoked dialysate glutamate levels were lower in the cerebral cortex of adul…

MaleAgonistmedicine.medical_specialtyMicrodialysisTime FactorsCannabinoid receptormedicine.drug_classMicrodialysisMorpholinesGlutamic Acidmaternal marijuana consumptionNaphthalenesBiologyTimechemistry.chemical_compoundGlutamatergicPiperidinesPregnancyInternal medicinebasal and K -evoked glutamate levelsmedicineAnimalsDrug InteractionsWakefulnessNeurotransmitterReceptorSR141716A; basal and K+-evoked glutamate levels; maternal marijuana consumptionCerebral CortexAnalysis of VarianceDose-Response Relationship DrugCannabinoidsGeneral NeuroscienceGlutamate receptorBenzoxazinesRatsEndocrinologyAnimals NewbornchemistryPrenatal Exposure Delayed EffectsSR141716AToxicityPotassiumPyrazolesSR141716A; basal and K -evoked glutamate levels; maternal marijuana consumption.CalciumFemaleRimonabantExtracellular Space
researchProduct

Serotonergic modulation of rat pineal gland activity: in vivo evidence for a 5-Hydroxytryptamine(2C) receptor involvement

2000

There are some suggestions that, in the pineal gland, serotonin acts not only as a precursor of melatonin but also plays a role in the modulation of the pineal biosynthetic activity. To corroborate this possible neuromodulatory role of 5-hydroxytryptamine (serotonin) (5-HT) on the pineal gland, the effects of two 5-HT(2) receptor agonists meta-chlorophenylpiperazine (m-CPP) and 1-(2, 5-dimethoxy-4-iodophenyl)-2-aminopropane were assessed in vivo on pineal N-acetyltransferase (NAT) activity and melatonin content in rats. m-CPP potentiated the enhancement of NAT activity and pineal melatonin content induced by isoproterenol administration during daytime, whereas it did not affect the diurnal …

MaleArylamine N-Acetyltransferasepineal glandAmphetaminesIsoproterenolPiperazinesserotoninergic modulation5-hydroxytryptamineRatsReceptors SerotoninReceptor Serotonin 5-HT2CSettore BIO/14 - FarmacologiaAnimalsRats WistarMelatonin
researchProduct

Osteonecrosis detected by whole body magnetic resonance in patients with Hodgkin Lymphoma treated by BEACOPP

2016

Objectives: The purpose of our retrospective review of prospectively acquired Whole Body Magnetic Resonance (WB-MRI) scans was to assess the incidence of osteonecrosis in patients who received different chemotherapies. Methods: We evaluated the WB-MRI scans performed on 42 patients with Hodgkin Lymphoma treated by three chemotherapy regimens (6ABVD, 2ABVD + 4BEACOPP, 2ABVD + 8BEACOPP), excluding patients with the main risk factors for osteonecrosis. Results: Six out of seven patients (86 %) who received eight BEACOPP and one out of five patients (20 %) treated by four BEACOPP presented osteonecrosis, with a statistically significant difference of frequency between the two groups of patients…

MaleBEACOPPLymphomamedicine.medical_treatmentProcarbazine030218 nuclear medicine & medical imaging0302 clinical medicinePrednisoneAntineoplastic Combined Chemotherapy ProtocolsMedicineWhole Body ImagingEtoposideIncidenceOsteonecrosisGeneral MedicineMiddle AgedHodgkin DiseaseMagnetic Resonance ImagingVincristine030220 oncology & carcinogenesisOsteonecrosiFemaleRadiologymedicine.drugAdultVincristinemedicine.medical_specialtyAdolescentCyclophosphamideDrug Administration ScheduleBleomycinYoung Adult03 medical and health sciencesImage Interpretation Computer-AssistedHumansRadiology Nuclear Medicine and imagingCyclophosphamideGlucocorticoidsNeoplasm StagingRetrospective StudiesDose-Response Relationship Drugbusiness.industrymedicine.diseaseLymphomaABVDDoxorubicinProcarbazinePrednisonebusinessComplicationBEACOPPEuropean Radiology
researchProduct

Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.

2007

Abstract While most of the studies concerning the role of cannabinoids on gastric motility have focused the attention on the gastric emptying in in vivo animal models, there is little information about the cannabinoid peripheral influence in the stomach. In addition, the functional features of CB2 receptors in the gastrointestinal tract have been poorly characterized. The purpose of the present study was to investigate the effects of cannabinoid drugs on the excitatory cholinergic and inhibitory non-adrenergic non-cholinergic (NANC) neurotransmission in mouse isolated gastric preparations. Intraluminal pressure from isolated whole stomach was recorded and mechanical responses induced by ele…

MaleCB1 receptorCannabinoid receptorIndolesmedicine.medical_treatmentGastric motilityReceptors PresynapticSettore BIO/09 - FisiologiaSynaptic TransmissionReceptor Cannabinoid CB2MicePiperidinesReceptor Cannabinoid CB1Cannabinoid receptor type 2StomachCholinergic Fiberslipids (amino acids peptides and proteins)Rimonabantmedicine.drugAgonistmedicine.medical_specialtyCarbacholmedicine.drug_classPolyunsaturated AlkamidesMorpholinesNeuromuscular JunctionArachidonic AcidsBiologyIn Vitro TechniquesNaphthalenesInternal medicineCannabinoid Receptor ModulatorsmedicineAnimalsCannabinoidPharmacologyEnteric neurotransmissionGastric emptyingCannabinoidsExcitatory Postsynaptic PotentialsCB2 receptorElectric StimulationBenzoxazinesMice Inbred C57BLEndocrinologyInhibitory Postsynaptic PotentialsCholinergicPyrazolesCannabinoidGastrointestinal MotilityGastric motilityEndocannabinoidsPharmacological research
researchProduct